Day: June 15, 2022

Changes in the Uponor Executive Committee

Written by Customer Service on June 15, 2022. Posted in Public Companies.

Andres Caballero Andres Caballero has been appointed President of Uponor’s Building Solutions – North America division and a member of the Executive CommitteeUponor Corporation, Stock exchange release, 15 June 2022 at 08:00 am EEST Changes in the Uponor Executive Committee Andres Caballero (M.Sc. Engineering, b. 1974) has been appointed President of the Building Solutions – North America division and a member of the Executive Committee at Uponor from 1 August 2022 at the latest. He will be based in Minnesota, USA and report to Michael Rauterkus, President and CEO, Uponor Corporation. Andres succeeds Bill Gray who stepped down from his role as President of Building Solutions – North America on 10 January 2022 to focus on interests outside the company. Current interim President of Building Solutions – North America, John Reutter...

WISeKey to Reverse Split its ADS on June 22, 2022

Written by Customer Service on June 15, 2022. Posted in Public Companies.

WISeKey to Reverse Split its ADS on June 22, 2022 Geneva, Switzerland, June 15, 2022 – Ad-Hoc announcement pursuant to Art. 53 of SIX Listing Rules– WISeKey International Holding Ltd. (NASDAQ: WKEY / SIX: WIHN) (“WISeKey” or the “Company” or the “Group”), a leading cybersecurity and IoT company, announced today a 1-for-2 reverse split of American Depository Shares (“ADS”) listed on the NASDAQ under the ticker “WKEY.” Under the current ratio, 1 ADS represents 5 Class B common shares listed on the Swiss Stock Exchange which means that, post-split 1 ADS will represent 10 Class B common shares. The number of shares owned by ADS holders will be adjusted after the closing bell on Wednesday, June 22, 2022. There will be no change to the total number of the Company’s Class B common shares. The ADS holders of record on the effective date of the...

Press release Biocartis Group NV: Biocartis Reaches Key Commercial Milestones: One-Millionth Idylla™ Cartridge Sold and 2,000th Idylla™ Instrument Placed

Written by Customer Service on June 15, 2022. Posted in Earnings Releases And Operating Results.

PRESS RELEASE: 15 June 2022, 07:00 CEST Biocartis Reaches Key Commercial Milestones: One-MillionthIdylla™ Cartridge Sold and 2,000thIdylla™ Instrument Placed Mechelen, Belgium, 15 June 2022 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces a double milestone today: the selling of its one-millionth commercial Idylla™ cartridge and the placement of its 2,000th Idylla™ instrument since its commercial launch. These events mark a key commercial milestone for Biocartis, which has been commercializing its rapid and easy-to-use decentralized Idylla™ molecular diagnostics platform in more than 70 countries across the world since 2015. Biocartis launched its first commercial products, the Idylla™ instrument and the Idylla™ BRAF Mutation Test (CE-IVD), in the European...

Clariant reports markedly stronger sales growth and EBITDA expansion in Q1 2022

Written by Customer Service on June 15, 2022. Posted in Earnings Releases And Operating Results.

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR First quarter 2022 sales from continuing operations increased by 30 % in local currency and 26 % in Swiss francs to CHF 1.262 billion – pricing contributed 16 % to the strong top–line growth Continuing operations EBITDA was up 27 % to CHF 220 million EBITDA margin increased to 17.4 % from 17.3 % in the first quarter of 2021 First quarter performance underlines the ability to achieve mid-term targets Outlook 2022: Strong local currency growth for the Group with the aim to improveyear-on-year Group EBITDA margin level in a challenging geopolitical environment“I’m proud to announce that Clariant had a strong start to 2022 despite the turbulent environment. In the first quarter, we successfully generated compelling revenue growth and clearly increased absolute EBITDA. The Group’s higher-value...

Grieg Seafood ASA: Capital Markets Day 2022

Written by Customer Service on June 15, 2022. Posted in Public Companies.

Short-term and long-term targets reaffirmed and sustainable growth platform beyond 2026 well established Grieg Seafood is hosting a Capital Markets Day outside Stavanger, Norway today 15 June 2022 under the headline “Farming the ocean for a better future”. Grieg Seafood has farmed salmon for almost three decades and the company is today one of the world’s leading salmon farmers. The Grieg Seafood operations are concentrated in Norway and Canada. The ocean has the potential to provide low impact food for generations to come and sustainable farming practices are the foundation of the company’s operations. Grieg Seafood today confirmed its growth ambitions with a target of annual harvest volume of 90 000 tonnes in 2022 and 120-135 000 tonnes in 2026 depending on successful utilization of current capacity, available expansion...

Active Health Foods, Inc. to Focus on Anti-Aging Business

Written by Customer Service on June 15, 2022. Posted in Public Companies.

Los Angeles, CA, June 14, 2022 (GLOBE NEWSWIRE) — Active Health Foods, Inc. (OTC: AHFD) announced today that it has discontinued the previously announced business plans in the Energy Food Bars, Cannabis, and in the Coinchamp.com crypto-currency businesses. Effective last week, in conjunction with the acquisition of Bioidentical Hormones Inc. www.bio-hormones.com (BIO) and its wholly owned subsidiary, Australian Menopause Centre www.menopausecentre.com.au (AMC), AHFD shall focus only on the Anti-Aging Medicine Industry. Mr. Glen Bonilla, the former controlling shareholder and CEO, and Mr. Gregory Manos, are no longer affiliated with the Company. AHFD will continue to operate and expand its skin care company, Etrnl Cosmetics, which has a unique chaga mushroom product for healthy skin. The Company will be making some significant...

VectivBio Announces Pricing of $30 Million Public Offering of Ordinary Shares

Written by Customer Service on June 15, 2022. Posted in Public Companies.

Combined Gross Proceeds from Public Offering and Private Sale Total $50 Million BASEL, Switzerland, June 14, 2022 (GLOBE NEWSWIRE) — VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the pricing of a follow-on public offering of 5,715,000 ordinary shares at a public offering price of $5.25 per share for aggregate gross proceeds of approximately $30 million, before deducting underwriting discounts and commissions and offering expenses. In addition, VectivBio has granted the underwriters a 30-day option to purchase up to an additional 857,250 ordinary shares at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about June 17, 2022, subject...

HEXO Reports Third Quarter 2022 Results

Written by Customer Service on June 15, 2022. Posted in Earnings Releases And Operating Results.

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated May 2, 2022 to its short form base shelf prospectus dated May 7, 2021 and amended and restated on May 25, 2021. (All $ figures in Canadian thousands unless otherwise stated) GATINEAU, Quebec, June 14, 2022 (GLOBE NEWSWIRE) — HEXO Corp (TSX: HEXO; NASDAQ: HEXO) (“HEXO” or the “Company”), a leading producer of high-quality cannabis products, today reported its financial results for the fiscal quarter ended April 30, 2022 (Q3’22). All amounts are expressed in Canadian dollars unless otherwise noted. “HEXO is committed to streamlining our operations across all functions, allowing our top-selling brands to remain competitive in the marketplace whilst aligning to our long-term financial objectives...

Day One Announces Pricing of Upsized Public Offering of Common Stock

Written by Customer Service on June 15, 2022. Posted in Public Companies.

SOUTH SAN FRANCISCO, Calif., June 14, 2022 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the pricing of its upsized underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $15.00 per share. All shares of common stock are being offered by Day One. The gross proceeds to Day One from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $150.0 million. In addition, Day One has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of its common stock at the public offering price, less underwriting...

Day: June 15, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals